Beaumont Health: SINK COVID-19 Study - Can Common Drugs Offer 2-Step Approach to Combat Deadly Virus?
May 05, 2020
May 05, 2020
ROYAL OAK, Michigan, May 5 -- Beaumont Health issued the following news release:
Researchers at Beaumont Hospital, Royal Oak have begun enrolling patients in a new clinical study aimed at treating COVID-19 patients with two common drugs - naltrexone and ketamine. It's called SINK COVID-19, or the Study of Immunomodulation using Naltrexone and Ketamine for COVID-19.
The single center, randomized study is only for patients, 18 years and older, hospitalized at Beaumont, Ro . . .
Researchers at Beaumont Hospital, Royal Oak have begun enrolling patients in a new clinical study aimed at treating COVID-19 patients with two common drugs - naltrexone and ketamine. It's called SINK COVID-19, or the Study of Immunomodulation using Naltrexone and Ketamine for COVID-19.
The single center, randomized study is only for patients, 18 years and older, hospitalized at Beaumont, Ro . . .